Attorney Docket No. 0149

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231

on this 21 day of June 2002

Keith D. Hutchinson

JUN 2 6 2002 TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
Fish, et al)	
)	
Serial No.: 10/109756)	Group Art Unit: 1646
)	
Filed: March 29, 2002)	Examiner: To be assigned
,)	
For: 3-Heterocyclylpropanohydroxamic Acid PCP)	
Inhibitors)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)

Assistant Commissioner For Patents Washington, D.C. 20231

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)--i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

Copies of the cited documents are enclosed. A copy of the International Search Report for International Application No. PCT/IB02/00817 is enclosed.

All of the cited art documents are in the English language.

It is respectfully requested that the Examiner confirm consideration of the cited

documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.

100

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 150850.

Date: June 21, 2002

Respectfully submitted,

Keith D. Hutchinson

Registration No. 43,687

Agouron Pharmaceuticals, Inc.

Legal Department

10350 North Torrey Pines Road

La Jolla, CA 92037

Phone: (858) 526-4608

JUN 2 1 2002 W

Sheet	1	1	of	1	
OHCC.			-	 	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE SYTTY. DOCKET NO. PATENT AND TRADEMARK OF 10149-US

10/109756

SERIAL NO. RECEIVED

INFORMATION DISCLOSURE CITATION BY APPLICANT

APPLICANT Fish, et al. JUN 2 6 2002

(Use several sheets if necessary)

Fish, et al.

G

GROUP/ANTENTER 1600/2900

March 29, 2002 U.S. PATENT DOCUMENTS

	CUN	IENT	NU	MBE	ER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
$\neg \dagger \neg$	\neg	7	T							
		$oldsymbol{\perp}$			Ц					
_	_	4	↓_	<u> </u>	Ш					
$-\!\!\!\!+\!\!\!\!\!+$	+	+	+		$\vdash \downarrow$					
	+	╁	╁	-	\vdash					
$\dashv \dagger$	+	╁	╁	-						
-++	+	+	╁╴		\vdash					L
									EODEICNI DATENT DOCUMENTS	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER						BER	DATE COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)	
	0	0	3	7	4	3	6	29.06.00	PCT	C07C	311/27	
	0	0	5	1	9	9	3	08.09.00	PCT	C07D	277/00	
	0	0	5	1	9	9	3 A3	08.09.00	PCT	C07D	277/36	
	9	7	0	5	8	6	5	20.02.97	PCT	A61K	31/215	
	9	9	4	5	9	2	7	16.09.99	PCT	A61K	31/44	
	0	1	4	7	9	0	1	05.07.01	PCT	C07D	271/06	
	9	5	2	3	7	9	0	08.09.95	PCT	C07D	233/64	
			_			_				1		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

UIF	IER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Yamamoto, M. et al., J. Med. Chem Vol. 41, No.8 April 1998 pp.1209-1217
	Steinman, DH., et al., Bioorganic & Med. Chem. Letters Vol. 8 No.16 August 1998 pp. 2087-2092
	Vu, CB., et al., Bioorg & Med. Chem Letters Vol. 9, No. 20 October 1999 pp. 3009-3014
	McClure et al., Bioorg & Med. Chem. Letters Vol. 8, No. 2 January 1998 pp.143-146
	Evans, DA., et al., J. Org. Chem., Vol.64 No.17, August 1999 pp.6411-6417
	Simoneau, B., et al., Bioorg. & Med. Chem. Vol. 7, No. 3, March 1999 pp.489-508
	Floyd, CD., et al., SynLett Vol. 6 June 1998 pp. 637-639
	Fray, et al., Tetrahedron, Vol. 54, No. 45 November 1998 pp. 13825-13832
	Dankwardt, SM, et al., Bioorg.& Med. Chem., Vol. 10, No. 22, November 2000 pp. 2513-2516
	Fray, et al., Bioorg. & Med. Chem., Vol. 11, No. 4, February 2001 pp. 567-570
	
	I I

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.